Background: A dedicated clinic for older women with early primary breast cancer, established in 1973, has recently evolved into a combined surgical/oncology facility. This study aimed to compare the clinical outcome across these periods.
introduction Breast cancer risk increases with age [1, 2] . With an ageing population, this becomes a major health issue, but clear management guidelines for older women are scarce, due to their minimal representation in trials. Their management is often copied from their younger counterparts and they are at risk of being over-or under-treated.
Over the last few decades, evolving clinical evidence has been influencing the pattern of treatment in older women with breast cancer, e.g. introduction of tamoxifen, availability of estrogen receptor (ER) status, axillary surgery and application of prognostic factors [e.g. Nottingham Prognostic Index (NPI) [3] ] in deciding for adjuvant systemic therapy. Clinical trials showing negligible difference in overall survival (OS) [4] , when surgery was compared with primary endocrine therapy (PET), have impacted on their therapeutic options. There is, however, little literature describing the changes in management pattern and their impact on long-term clinical outcome.
A dedicated Primary Breast Cancer Clinic for Older Women (the Clinic) was established in Nottingham Breast Unit at its inception in 1970s. This study aimed to describe the evolving changes in management and long-term clinical outcome over time.
methods patients
As part of an ongoing research programme on early operable primary breast cancer in older women, a database was established, including 1758 women, fulfilling the criteria below, managed in the Clinic from 1973 to 2010. The patients were first identified from paper (before 1987, N = 240) and computerised (since 1987 , N = 1518) records in Histopathology Department. All patients were ‡70 years of age, who had early operable primary breast cancer (clinically £5 cm) without evidence of metastases at diagnosis.
For patients identified from the histopathology records, clinical data were retrospectively collected from case notes, including detailed clinical information from the date of diagnosis till death/last follow-up. The dataset was based on variables recorded for the primary breast cancer series used to derive the NPI [3, 5] for patients treated by surgery. For patients on nonoperative therapies (predominantly PET), clinical responses at 6 months, progression status and time to progression were recorded for all lines of therapy and best response recorded only for first-line therapy.
treatment protocols
All patients were treated following the same clinical guidelines at any time point. They had been changing due to evolving clinical evidence.
1973-1989.
Patients were offered surgery; those who refused or were unfit were given tamoxifen. ER status was not routinely assessed and there were no standard selection criteria for adjuvant systemic therapy.
1990-1999. ER status was routinely assessed. Patients with ER-positive invasive carcinoma were given the choice of surgery or PET, while those with ER-negative tumours were offered surgery. The patients undergoing surgery had the option of mastectomy or breast conservation [wide local excision (WLE)] as appropriate. Axillary surgery was only considered when there were clinically palpable lymph node(s) (LNs). Patients who underwent WLE were given no further treatment, adjuvant endocrine therapy and/or radiotherapy, depending on clinical judgement, based on consideration of tumour grade, margin status, degree of ER positivity and LN status if available.
For patients who received PET, tamoxifen was the drug of choice. Patients with contraindications (e.g. thromboembolism) were offered an aromatase inhibitor (AI) such as anastrozole, since it became available in 1995. When patients progressed on first-line PET, treatment options included surgery, further PET or primary radiotherapy. The decision of second-line therapy was based on patient's choice, fitness, prior response to PET and development of metastases.
Patients with ER-negative tumours who refused or were unfit for surgery were offered primary radiotherapy.
2000-2010.
The treatment protocol was more structured and all patients were discussed at a multidisciplinary team meeting before they were seen in the Clinic (which had evolved from a surgical clinic to become a combined surgical/oncology facility during this period).
Individual treatment recommendation was based on a joint assessment of the surgeon, oncologist and breast cancer nurses in the Clinic.
All patients were recommended to have surgery (mastectomy or WLE as appropriate). Axillary surgery (four-node sampling with introduction of blue dye sentinel node biopsy recently or level III axillary clearance for LN-positive cases proven preoperatively) became part of standard surgery. Intact breast irradiation was normally given following WLE unless the patient was on adjuvant endocrine therapy. Post-mastectomy chest wall irradiation was normally given if the tumour had two of three features-grade 3, positive LN and vascular invasion. For patients with ERpositive invasive carcinoma, those with NPI ‡3.4 (moderate/poor prognosis) received adjuvant endocrine therapy using an AI. Those with NPI 3-3.4 (good prognosis) were given the option of no adjuvant endocrine therapy or tamoxifen. Those patients with NPI <3 (excellent prognosis) did not receive any systemic therapy. Adjuvant chemotherapy with/without trastuzumab, depending on human epidermal growth factor receptor 2 (HER2) status, was considered in fit 'younger' patients with moderate/poor prognostic tumours, especially when they were ER negative.
Patients with ER-positive tumours who refused or were unfit for surgery were given PET, and those with ER-negative tumours were offered primary radiotherapy.
follow-up protocol
All patients were followed up in the Clinic. Patients treated surgically were followed up on a yearly basis and as required. Patients on non-operative therapies were followed up at 6 weeks, 3 months, thereafter 6-monthly and as required. Response was assessed clinically by callipers using International Union Against Cancer criteria [6] , with adherence to British Breast Group recommendations [7] .
tumour characteristics
Histology was reported by a single team of pathologists following the same guidelines at any time point. Positive ER status, based on core biopsies, was defined by histochemical score (H score) ‡50, using immunohistochemistry (IHC) [8] . In the earlier period, charcoal-coated method was used in three cases, with positivity defined as ‡5 fmol of cytosolic protein equivalent to Allred score of 5 [9] and H score ‡50.
Tumour grade and axillary stage were recorded from surgical specimens-grade defined by the modified Scarf-Bloom-Richardson [10] criteria and categorised as 1-3 and stage defined by the quantitative score of positive axillary LNs: stages 1, 0 LN; 2, 1-3 LN and 3, ‡4 LN positive.
During the last 3 years, standard reporting of ER, progesterone receptor (PR) and HER2 based on core biopsies at diagnosis became routine. Based on standard UK pathology guidelines, ER/PR status was measured using IHC [for the purpose of assessing the rate of triple-negative cancers (see in 'Results' section), positivity was defined as H score ‡1]. HER2 positivity was defined as IHC 3+ or FISH score >2.0.
outcome variables
Survival, metastases and contralateral tumour development were recorded for all patients. Breast cancer-specific survival (BCSS) was calculated from the date of diagnosis till death from breast cancer. OS was calculated from diagnosis till death regardless of cause. The causes of death were categorised into breast cancer deaths (breast cancer as the first cause of death on the death certificate) and non-breast cancer deaths (as on the death certificate or for women with unknown causes of death, if they died within 1 year of last follow-up without clinical evidence of metastases). The causes of death were recorded from case notes, supplemented by information from the general practitioners for those patients who were discharged back to their care, due to patient preference.
Metastases were defined as tumour appearance at distant sites (contralateral axillary LN, ipsilateral/contralateral supraclavicular LN, bones, liver, lung, etc.) and the time to metastases was calculated from diagnosis.
Contralateral tumour referred to appearance of a new primary in the opposite breast with the time to contralateral tumour calculated in the same way as above.
Patients treated by surgery had additional outcome variables recorded. Local recurrence (LR) was defined as tumour appearance in the ipsilateral breast after WLE or in the mastectomy flap. Regional recurrence (RR) was defined as appearance of tumour in the ipsilateral axilla. Time to LR/RR was calculated from the time of surgery.
statistical methods
The Statistical Package for Social Sciences version 16.0 (Chicago, IL) was used as data analysis tool. Statistical significance was defined by P value <0.05. The pattern of time-dependant variables was analysed using Kaplan-Meier plots, supplemented by life table analysis with application of log-rank and Wilcoxon tests as appropriate. (Table 1) .
Patients treated by surgery tended to have grade 2 (41.7%) or 3 (42.4%) tumours and most had LN-negative disease (61.4%). There was a tendency towards a higher proportion of the latter in recent years though the number in the earlier period was small as axillary surgery was not standard.
During the most recent 3 years when ER/PR/HER2 status was routinely available (N = 97), 13.4% and 8.2% had triplenegative and HER2-positive disease, respectively (supplemental Table S1 , available at Annals of Oncology online) [11] .
pattern of treatment Surgery (49.1%) and PET (48.8%) were the predominant primary treatments and a small proportion of patients received primary radiotherapy (1.2%). PET was used more often in the earlier period ($60% versus 41% before and after 2000, respectively). In all periods, patients who received nonoperative therapies were generally older when compared with those who underwent surgery (median age for surgery, PET and radiotherapy = 75, 80 and 79 years, respectively) ( Table 1) .
The rate of breast conservation increased with time (<10% in 1970s versus $40% in 2000s; Table 1 ). Also, axillary surgery became part of standard surgical therapy in the recent decade ($90%). The pattern of surgery according to clinical size has changed with proportionately more patients having breast conservations (Table 2) .
There was a gradual move towards giving more adjuvant therapies recently ( 
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to LR improved significantly after 1999 (supplemental Table S2 , available at Annals of Oncology online; Table 3 ; Figure 1 ). RR rate was 1.2% per annum for the whole series (1973-1989, 2.5%; 1990-1999, 1.1%; 2000-2010, 0.4%). Time to RR improved significantly in recent years (P < 0.001; Table 2;  supplemental Table S2 , available at Annals of Oncology online; Figure 1 ). whole series. For the whole series, the rate of contralateral tumours was extremely low at 0.7% per annum (1973-1989, 0.8%; 1990-1999, 0.6%; 2000-2010, 0.4%), with no significant changes throughout. The rate of metastases was 2.6% per annum overall (1973-1989, 3.1%; 1990-1999, 2.8%; 2000-2010, 1.5%). Time to metastases improved significantly in recent years (after 2000; P < 0.001; Table 2; supplemental Table  S2 , available at Annals of Oncology online).
The 5-year BCSS showed a significant improvement over time, being greatest in the recent decade (81% versus 91% before and after 2000, respectively, P < 0.001). The 5-year OS has also improved (56% versus 71% before and after 2000, respectively, P < 0.001; supplemental Table S2 , available at Annals of Oncology online; Figure 2 ).
discussion
The results show that within this elderly cohort, comparatively older patients were seen and they presented with smaller tumours in recent years, in addition to increased availability of ER status and rates of axillary staging and breast conservation. Furthermore, a greater proportion received adjuvant therapies. Regardless of treatment given, their clinical outcome appeared very good throughout and further improved.
Older women with breast cancer comprise a heterogeneous group of individuals due to co-morbidities, limited physiological reserve and life expectancy and social issues. Clinical guidelines based on younger patients may be inappropriate. There is an urgent need of robust data from this population. Randomised controlled trials (RCTs) have been the standard used to change clinical practice, but there is often inappropriate or inadequate representation of older women in major trials. There are barriers (e.g. co-morbidities, social dependency) resulting in the failure of trials focusing on this population [12] . The Endocrine +/2 Surgical Therapy for Elderly Women with Mammary cancer (ESTEeM) and Adjuvant Cytotoxic Chemotherapy in Older Women (ACTION) trials are examples. They aimed to answer very important questions specific to this group of patients but unfortunately closed prematurely due to slow recruitment. Given this context, the importance of non-randomised studies cannot be underestimated. Studies with long-term follow-up and clear protocol modifications have the potential to analyse the impact of treatment and also to provide evidence for establishing management guidelines.
This study being from a single centre, with patients managed in a dedicated service according to agreed management protocols, provides long-term clinical outcome data for nearly four decades. It therefore has the potential to answer some important questions and also to set directions for future research for this population.
The increasing average age over time is in keeping with recent statistics showing longevity. A greater population of this series had ER-positive, low-grade and early-stage disease, as previously described in the literature [13, 14] . The European Oncopool database showed a gradual decline of grade 3 tumours as age advances (68% at 30 years versus 30% at 70) [15] . Despite the fact that most patients in this series presented symptomatically (the National Screening Programme did not cover this age group), majority still had early-stage disease. Axillary surgery has now become standard. Recently published non-randomised retrospective data from a single centre after a median follow-up of 15 years, including 671 (axillary surgery N = 172 versus no axillary surgery N = 499) older ( ‡70 years) women, showed no additional benefit of axillary dissection in terms of BCSS [16] . Regardless of receptor status, tamoxifen was given to all patients in the study, though majority (91.6%) showed hormone positivity [16] . This suggests that in older patients taking adjuvant endocrine therapy for ER-positive tumours, the benefit of additional axillary clearance may be small. However, axillary status remains important for deciding for adjuvant therapies. Therefore, staging the axilla cannot be completely avoided in older women.
The rates of PET and surgery were approximately the same in the cohort. This is due to the popularity of PET during 1990s as a result of small RCTs showing no significant difference in survival between surgery and tamoxifen. Therefore, patients during that era were given the choice of PET or surgery. It seems that a greater proportion opted for PET. A UK-based audit presented reasons of PET use: being unfit for surgery (N = 21, 38%), patients own choice (N = 17, 31%) or extreme age (N = 4, 7%) [17] . Extreme age is also evident from the upper age for surgery and PET being 92 and 99 years, respectively, in original articles Annals of Oncology our series. Based on a study of patients whom we treated recently, when patients were given a choice, they were more likely to opt for non-operative therapies than surgery [18] . Majority of the patients in recent years received adjuvant endocrine therapy with/without radiotherapy. Recently, an update of an RCT [N = 636 older women; adjuvant tamoxifen (N = 319) with/without postoperative irradiation after lumpectomy] after a median follow-up of 10.5 years showed no additional benefit of radiotherapy when adjuvant tamoxifen was given in ER-positive tumours [19] . However, there was a small (6%) absolute improvement in LR in the radiotherapy arm as compared with tamoxifen alone. Thus, the decision of radiotherapy following WLE in older women should be made cautiously bearing tumour biology (e.g. degree of ER positivity), use of adjuvant endocrine therapy, life expectancy and general physical status in mind.
We would have liked to investigate the impact of adjuvant chemotherapy with/without trastuzumab on survival, especially in patients with triple-negative/HER2-positive disease, due to routine availability of ER/PR/HER2 status. However, as explained earlier, this has only happened in the most recent 3 years, so a meaningful survival analysis was deemed impossible given the small number (N = 97) and short duration of follow-up.
Analysis of different types of survival data is particularly important in the older population. OS describes the whole 
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picture taking into account of all deaths, including competing causes of deaths not due to breast cancer, which potentially contribute to most deaths in the elderly. BCSS takes specific account of deaths due to breast cancer and provides a very good measurement of tumour biology. Relative survival (based on the relative proportion of deaths in patients with breast cancer and in the general population), often measured by cancer registries, provides some indication of tumour biology and impact of treatment-related problems. It is an indicator close to but not exactly the same as BCSS.
The clinical outcome appears excellent in this series regardless of management pattern and has further improved in the recent decade. The survival data were comparable with other figures. The 5-year BCSS in older women from the East Midlands (same region) was 94.5% and 84.2%, respectively, in stage I and II disease, though only 59% of patients were staged [20] . Recently published UK data including 14 048 patients >50 years of age with breast cancer diagnosed from 1999 to 2007 show that the 5-year breast cancer relative survival rates in the age groups 70-74, 75-79 and ‡80 years were, respectively, 81%, 76% and 70%. Although the figures were regardless of disease stage, 84%, 80% and 74% had stage I/II disease in each age group, respectively [21] . Furthermore, within the same respective age groups, 15%, 27% and 58% patients received non-operative therapies as primary treatment and for those who underwent surgery, only 7%, 3% and 1% had adjuvant chemotherapy, respectively.
Most available studies demonstrate a general improvement in survival for women with breast cancer over the last few decades but data stratified by age and stage are scarce to allow a precise comparison [21] [22] [23] [24] . Our study is one of the few focusing on long-term clinical outcome specific to older women with early (stage I/II) operable primary breast cancer.
In this recent decade, while surgery became the predominant treatment, a significant proportion of patients ($40%) had non-operative therapies, selection of which was based on assessment in the Clinic. This management approach appears to produce excellent clinical outcome, which is significantly better than earlier period. While surgery might be perceived as the 'best' primary treatment with a curative intent for all patients with primary operable breast cancer, it may not be appropriate in the elderly population. The set-up of a dedicated clinic described here allows multidisciplinary assessment of individual patients. Over the years, the Clinic has evolved into a combined surgical/oncology facility supported by dedicated breast care nurses, all with a special interest and experience in the management of this group of patients. Recently, a pilot study investigating the use of a comprehensive geriatric assessment tool has also begun. All these aim to provide a platform to personalise the treatment of older women with primary breast cancer taking into account of the individuals' physical (e.g. tumour biology, comorbidities) and psychosocial (e.g. social support, patient choice, quality of life) needs. The results of this study clearly indicate a selective use of surgery and non-operative therapies could produce excellent clinical outcome for this population. Further work is required to tease out all the factors in operation to enable optimal selection of management strategies. 
